BR9910511A - Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento - Google Patents

Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento

Info

Publication number
BR9910511A
BR9910511A BR9910511-0A BR9910511A BR9910511A BR 9910511 A BR9910511 A BR 9910511A BR 9910511 A BR9910511 A BR 9910511A BR 9910511 A BR9910511 A BR 9910511A
Authority
BR
Brazil
Prior art keywords
radiation
treatment
growth factor
tyrosine kinase
receptor tyrosine
Prior art date
Application number
BR9910511-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Harlan W Waksal
Mansoor N Saleh
Francisco Robert
Donald Jay Buchsbaum
Original Assignee
Imclone Systems Inc
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Uab Research Foundation filed Critical Imclone Systems Inc
Publication of BR9910511A publication Critical patent/BR9910511A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9910511-0A 1998-05-15 1999-05-14 Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento BR9910511A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US20613898A 1998-12-07 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
BR9910511A true BR9910511A (pt) 2001-11-20

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910511-0A BR9910511A (pt) 1998-05-15 1999-05-14 Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento

Country Status (14)

Country Link
EP (1) EP1080113A4 (cs)
JP (1) JP2002515511A (cs)
KR (1) KR20010071271A (cs)
CN (1) CN1314917A (cs)
AU (1) AU4079999A (cs)
BR (1) BR9910511A (cs)
CA (1) CA2332331A1 (cs)
CZ (1) CZ20004224A3 (cs)
HK (1) HK1040720A1 (cs)
IL (1) IL139707A0 (cs)
MX (1) MXPA00011248A (cs)
PL (1) PL348634A1 (cs)
SK (1) SK17282000A3 (cs)
WO (1) WO1999060023A1 (cs)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
EP1311291A4 (en) * 2000-08-09 2007-07-25 Imclone Systems Inc TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
DE60318561T2 (de) * 2002-04-02 2009-01-08 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1638600A4 (en) 2003-06-09 2008-06-11 Samuel Waksal PROCESS FOR INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRA CELLULAR ANTAGONIST
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
RS20060099A (en) 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
PL2100618T3 (pl) 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CL2007002404A1 (es) 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
WO2009030368A1 (en) 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Combination therapy with type i and type ii anti-cd20 antibodies
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
CN102470172B (zh) 2009-08-14 2014-09-24 罗切格利卡特公司 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2535503T3 (es) 2010-03-11 2015-05-12 Merrimack Pharmaceuticals, Inc. Uso de inhibidores de ErbB3 en el tratamiento del cáncer de mama triple negativo
MX342590B (es) 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
RU2013131444A (ru) 2010-12-16 2015-01-27 Рош Гликарт Аг Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
SG194111A1 (en) 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2852127C (en) 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
CN104136464A (zh) * 2012-02-23 2014-11-05 U3制药有限公司 用于调节放射敏感性的her3抑制剂
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
MX2015002947A (es) 2012-09-07 2015-09-23 Genentech Inc Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945B (zh) 2015-07-07 2025-01-28 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
MX2018006781A (es) 2015-12-03 2018-11-09 Agios Pharmaceuticals Inc Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2017125429A1 (en) 2016-01-18 2017-07-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
WO2019062755A1 (en) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
JP2021521219A (ja) 2018-04-18 2021-08-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｂｅｔ阻害剤およびプロテアソーム阻害剤を用いる併用療法
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0831880A4 (en) * 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
PL348634A1 (en) 2002-06-03
CA2332331A1 (en) 1999-11-25
IL139707A0 (en) 2002-02-10
JP2002515511A (ja) 2002-05-28
WO1999060023A1 (en) 1999-11-25
EP1080113A4 (en) 2002-04-17
CZ20004224A3 (cs) 2002-02-13
SK17282000A3 (sk) 2002-04-04
KR20010071271A (ko) 2001-07-28
AU4079999A (en) 1999-12-06
EP1080113A1 (en) 2001-03-07
HK1040720A1 (zh) 2002-06-21
MXPA00011248A (es) 2004-09-06
CN1314917A (zh) 2001-09-26

Similar Documents

Publication Publication Date Title
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
BR0007532A (pt) Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
DE60113815D1 (de) Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69519796D1 (de) PTPalpha-Bestimmung in der Tumordiagnose und -Prognose
BR9910792A (pt) Inibidores de quinase protéica 2-indolinona substituìda com pirrol
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
BR0311814A (pt) Método de tratar câncer empregando inibidores de cinase
MY128370A (en) Pyrrolotriazane inhibitors of kinases
BR0208373A (pt) Inibidores da tirosina cinase
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
PT768885E (pt) Metodo para inibir a metastizacao do cancro por administracao oral de pectina citrica modificada soluvel
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
FI972492L (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
BR0307522A (pt) Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea
DK1117783T3 (da) Gen udtrykt i prostatacancer

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]